RZLT’s 45% AH bump is surprising (IMO) given that the phase-2 trial did not show any improvement in BCVA. I realize that 12 weeks is a short duration in which to see a BCVA improvement, so the lack of such an outcome is not a major blemish. Still, if I were long I would have liked to see at least a small BCVA improvement.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.